Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2024 Informations relatives au nombre total de droits de...
Sanofi: Information concerning the total number of voting rights and shares - October 2024 Information concerning the total number of voting...
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Dupixent sBLA accepted for FDA review for...
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes...
Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée La FDA a...
Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué...
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Sarclisa...
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple...
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Dupixent approved in...
Communiqué de presse : Dupixent, premier et seul médicament approuvé dans l’UE pour le traitement de l’œsophagite à éosinophiles du jeune enfant...
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis...
Communiqué de presse : T3 2024 : Croissance des ventes de 15,7% soutenue par une séquence des ventes de vaccins plus favorable qu’anticipée;...
Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance...
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관